IINN - Public offerings

RA'ANANA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2025, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2025 marked a pivotal year for Inspira as we advanced from clinical validation into early commercial execution. Throughout 2025 and since year-end, we saw meaningful progress across multiple commercialization pathways for the INSPIRA™ ART100 system, including active clinical use at leading medical centers, advancement

RA'ANANA, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering priced at-the-market under Nasdaq Rules of an aggregate of 6,785,715 ordinary shares (or ordinary share equivalents in lieu thereof) at a purchase price of $0.70 per share. The gross proceeds to the Company from the offering are expected to be approximately $4.75 million, before deducting placement agent commi

RA'ANANA, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has entered into a definitive agreement with YA II PN, Ltd. ("YA") for a registered direct offering of its ordinary shares, and has also entered into a Standby Equity Purchase Agreement ("SEPA") with YA providing additional equity financing flexibility. Inspira has entered into a definitive agreement for the issuance and sale, in a registered direct offering, of an aggregate of 1,565,217 ordinary shares at a purchase price of $1.15 per

RA'ANANA, Israel, April 1, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) (the "Company" or "Inspira"), today announced a strategic investment by leading investor, Mr. Ronen Juster, and the mother of Inspira's Chief Executive Officer, Ms. Margi Ben-Noon. The Company has entered into a definitive agreement for the issuance and sale of an aggregate of 1,339,285 of ordinary shares at a price per share of $1.232, in a registered direct offering. The offering is expected to close on or about April 2, 2024, subject to the satisfaction of customary closing conditions. The proceeds to Inspira from the offering are expected to be $1.65 million Inspira currently inte

RA'ANANA, Israel, Dec. 28, 2023 /PRNewswire/ -- Inspira Technologies OXY BHN Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, today announces the closing of its previously announced registered direct offering of 3,031,250 ordinary shares (or ordinary share equivalents in lieu thereof), at a purchase price of $1.28 per ordinary share (or ordinary share equivalents in lieu thereof). Inspira has also issued in a private placement warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share. The warrants are exercisable immediately upo

RA'ANANA, Israel, Dec. 26, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW)  (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,031,250 of ordinary shares (or pre-funded warrants in lieu thereof) at a purchase price of $1.28 per share (or per pre-funded warrants in lieu thereof) in a registered direct offering. The Company has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 3,031,250 ordinary shares. The

RA'ANANA, Israel, Nov. 16, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a pioneer in acute respiratory care, today announced its financial results for the third quarter ended September 30, 2023. This quarter, Inspira continued to progress in the development of its novel technology for oxygenating blood, an alternative to traditional mechanical ventilation for respiratory patients. This patented technology, recently bolstered by a grant from the Israeli Innovation Authority and new U.S. patents, is at the heart of Inspira's strategy. Key business developments include the Company's preparation for U.S. Food and Drug Admin

As of June 30, 2023, the Company had $8.9 million in cash, cash equivalents and short-term bank deposits. RA'ANANA, Israel, Aug. 10, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a company aiming to revolutionize acute respiratory care, announced today its financial results for the second quarter ended June 30, 2023.     Outlook: INSPIRA™ ART100 - We are focused on the final stages of the development of the INSPIRA ART100, which is planned to be submitted to the U.S. Food and Drug Administration (the "FDA") clearance via the 510(k) pathway. We believe that the potential completion of the INSPIRA ART100 illustrates and va

As of March 31, 2023, the Company had $11.5 million in cash, cash equivalents, and short-term bank deposits RA'ANANA, Israel, May 18, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, announced today its financial results for the first quarter ended March 31, 2023. Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated:  "We believe that this is a very important period for the Company, as we continue to progress towards the regulatory submission of the New ALICETM Device with the U.S. Food and Drug Administration (FDA) in the coming months

As of December 31, 2022, the Company had $13.9 million in cash, cash equivalents, and deposits.  RA'ANANA, Israel, April 4, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) (the "Company" or "Inspira Technologies, a company aiming to revolutionize acute respiratory care, announced its financial results for the fourth quarter and year ended December 31, 2022.   Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: "We believe that the Company is well funded to achieve its immediate goals, advancing the building blocks of the INSPIRATM ART system. This includes the HYLATM blood sensor clinical studies currently underway and our ALICETM device,

As of September 30, 2022, the Company had $16.2 million in cash, cash equivalents, and short-term bank deposits RA'ANANA, Israel, Nov. 23, 2022 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today its financial results for the third quarter ended September 30, 2022.   Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: "Our research and development programs continue to progress towards meeting our strategic targets. In the first quarter of 2023 we plan to see an important component of the INSPIRA™ ART system, our HYLA™ blood sens

As of June 30, 2022, the Company had $19.2 million in cash RA'ANANA, Israel, Aug. 11, 2022 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today its financial results for the second quarter ended June 30, 2022.     Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: "The Company continues to meet its scheduled major objectives and improve its position within the target market of direct blood oxygenation. Our focus on contributing to medical advancement within this space is exemplified by the introduction of our new HYLA™, a non-i

As of March 31, 2022, the Company had $21.7 million in cash RA'ANANA, Israel, May 19, 2022 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today its financial results for the first quarter ended March 31, 2022.     Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: "The Company continues to be focused on meeting schedules in 2022 for its major milestones, which include revealing a new technology designed for utilization in the ART™ system. Inspira will also continue to drive towards strategic agreements and reach advanced stages

RA'ANANA, Israel, Nov. 23, 2021 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today its financial results for the third quarter ended September 30, 2021. "We believe that the exclusive agreement signed with WAAS Group for the potential deployment of more than 1,000 ART systems in Spain and Portugal led our investors to express their support by exercising most of the warrants issued in our IPO at an exercise price of $5.50 per share. Due to the exercise of these warrants, the number of our outstanding ordinary shares has increased. This additional capita

RA'ANANA, Israel, Aug. 13, 2021 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a specialty medical device company engaged in the research, development, manufacturing and marketing of proprietary respiratory support technologies, announced today its financial results as of and for the six months ended June 30, 2021. The Company has also released a corporate update.     "In order to achieve our Go-To-Market objective, we are exploring potential possibilities for partnerships with leading medical device companies, manufacturers, and distributors," said Dagi Ben-Noon, Inspira's CEO and one of its Co-Founders. "We estimate that our A